Research programme: eye disorder therapeutics - pSivida/Undisclosed company
Latest Information Update: 24 Jun 2015
At a glance
- Originator Undisclosed
- Developer pSivida; Undisclosed
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Eye disorders
Most Recent Events
- 12 May 2015 Early research in Eye disorders in USA (Ophthalmic)
- 12 May 2015 pSivida and an undisclosed leading global pharmaceutical company agree to evaluate Durasert™ drug delivery technology for eye disorder therapeutics